- Home
- BEAM vs ZD Comparison
BEAM vs ZD Comparison
Compare BEAM & ZD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAM
- ZD
- Stock Information
- Founded
- BEAM 2017
- ZD 1995
- Country
- BEAM United States
- ZD United States
- Employees
- BEAM N/A
- ZD N/A
- Industry
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- ZD Advertising
- Sector
- BEAM Health Care
- ZD Consumer Discretionary
- Exchange
- BEAM Nasdaq
- ZD Nasdaq
- Market Cap
- BEAM 1.6B
- ZD 1.3B
- IPO Year
- BEAM 2020
- ZD 1999
- Fundamental
- Price
- BEAM $19.18
- ZD $32.05
- Analyst Decision
- BEAM Strong Buy
- ZD Hold
- Analyst Count
- BEAM 11
- ZD 6
- Target Price
- BEAM $48.90
- ZD $49.67
- AVG Volume (30 Days)
- BEAM 2.0M
- ZD 590.0K
- Earning Date
- BEAM 08-05-2025
- ZD 08-06-2025
- Dividend Yield
- BEAM N/A
- ZD N/A
- EPS Growth
- BEAM N/A
- ZD 36.58
- EPS
- BEAM N/A
- ZD 1.76
- Revenue
- BEAM $63,578,000.00
- ZD $1,415,839,000.00
- Revenue This Year
- BEAM N/A
- ZD $7.37
- Revenue Next Year
- BEAM $8.82
- ZD $3.65
- P/E Ratio
- BEAM N/A
- ZD $18.28
- Revenue Growth
- BEAM N/A
- ZD 3.24
- 52 Week Low
- BEAM $13.53
- ZD $29.15
- 52 Week High
- BEAM $35.25
- ZD $60.62
- Technical
- Relative Strength Index (RSI)
- BEAM 60.60
- ZD 50.65
- Support Level
- BEAM $16.59
- ZD $29.90
- Resistance Level
- BEAM $20.46
- ZD $33.62
- Average True Range (ATR)
- BEAM 1.13
- ZD 1.40
- MACD
- BEAM 0.34
- ZD 0.10
- Stochastic Oscillator
- BEAM 70.61
- ZD 57.80
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
About ZD Ziff Davis Inc.
Ziff Davis Inc is a focused digital media and internet company whose portfolio includes brands in technology, entertainment, shopping, health, cybersecurity, and martech. It has two reportable segments: Digital Media and Cybersecurity and Martech. The company's brands include Mashable, Ookla, Offers.com, IGN, and VPN among others. The majority of revenue is generated from Digital Media.